Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy

Antibody–drug conjugates (ADCs) have provided new therapeutic options and significant promise for patients with cancer, particularly where existing treatments are limited. Substantial effort in ADC development is underway globally, with 13 ADCs currently approved and many more in development. The th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurwitz, Joshua, Haggstrom, Lucy Roxana, Lim, Elgene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458257/
https://www.ncbi.nlm.nih.gov/pubmed/37631232
http://dx.doi.org/10.3390/pharmaceutics15082017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458257/
https://www.ncbi.nlm.nih.gov/pubmed/37631232
http://dx.doi.org/10.3390/pharmaceutics15082017

Ejemplares similares